Dabrafenib and trametinib in BRAFV600E mutated glioma

BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CNS Oncol
Egile Nagusiak: Brown, Nicholas F, Carter, Thomas, Kitchen, Neil, Mulholland, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Future Medicine Ltd 2017
Gaiak:
Case Series
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/
https://ncbi.nlm.nih.gov/pubmed/28984141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak